An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 856-864

  Dummer, Reinhard ^a   Hauschild, Axel ^b   Becker, Juergen C ^c   Grob, Jean Jacques ^d   Schadendorf, Dirk ^e   Tebbs, Veronica ^f   Skalsky, Jeannine ^a   Kaehler, Katharina C ^b   Moosbauer, Stephanie ^c   Clark, Ruth ^f   Meng, Tze Chiang ^g   Urosevic, Mirjana ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f 3M Drug Delivery Systems   (United Kingdom)

^g 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CARBOPLATIN; CARMUSTINE; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CISPLATIN; DACARBAZINE; FOTEMUSTINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; IMATINIB; INTERFERON; INTERLEUKIN 2; MONTANIDE ISA 51; N [4 (4 AMINO 2 ETHYL 1H IMIDAZO[4,5 C]QUINOLIN 1 YL)BUTYL]METHANESULFONAMIDE; PEGINTERFERON; TEMOZOLOMIDE; THALIDOMIDE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST 852A; TREOSULFAN; UNCLASSIFIED DRUG; VINBLASTINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER STAGING; CHILL; CHOLESTASIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; MALAISE; MALE; MELANOMA; METASTASIS; MONOCYTE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SHOULDER PAIN; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; CHEMOKINE CXCL10; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE I; MALE; MELANOMA; MONITORING, IMMUNOLOGIC; PATIENT SELECTION; QUINOLINES; SKIN NEOPLASMS; SULFONAMIDES; TOLL-LIKE RECEPTOR 7;

EID: 38949100471     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1938     Document Type: Article

References (43)

1. Dummer R, Nestle FO. Melanoma vaccines in development: looking to the future. BioDrugs 2000;13:227-31.
2. Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma. Clin Dermatol 2004;22:251-65.
3. Dummer R, Garbe C, Thompson JA, et al. Randomized dose-escalation study evaluating peginterferon α-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006;24:1188-94.
4. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
5. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004;101Suppl 2:14639-45.
6. Medzhitov R, Janeway C, Jr. The Toll receptor family and microbial recognition. Trends Microbiol 2000;8:452-6.
7. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971-4.
8. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97:1143-53.
9. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135-8.
10. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6.
11. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-6.
12. Dudek AZ, Yunis C, Harrison LI, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor-7 (TLR7) agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13:7119-25.
13. Gorski KS, Waller EL, Bjornton-Severson J, et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006;18:1115-26.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
16. Burleson GR, Burleson FG. Bioassay of interferons. In: Burleson GR, Dean JH, Munson AH, editors. Methods in immunotoxicology. New York: Wiley-Liss, Inc.; 1995. p. 345-56.
17. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Med 1998;17:2301-12.
18. Kirkwood JM. Adjuvant interferon in the treatment of melanoma. Br J Cancer 2000;82:1755-6.
19. Pockros PJ, Guyader D, Patton H, et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007;47:174-82.
20. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 1996;74:1482-6.
21. Lee J, Wu CC, Lee KJ, et al. Activation of antihepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A 2006;103:1828-33.
22. Yrlid U, Cerovic V, Milling S, Jenkins CD, Klavinskis LS, MacPherson GG. A distinct subset of intestinal dendritic cells responds selectively to oral TLR7/TLR8 stimulation. Eur J Immunol 2006;36:2639-48.
23. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002;218:74-86.
24. Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005;201:1435-46.
25. Gangur V, Simons FE, Hayglass KT. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-γ over IL-4 responses. FASEB J 1998;12:705-13.
26. Yoneyama H, Narumi S, Zhang Y, et al. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med 2002;195:1257-66.
27. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
28. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
29. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 2003;47:3846-52.
30. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
31. Wrzesinski C, Restifo NP. Less is more: lympho-depletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based antitumor immunotherapy. Curr Opin Immunol 2005;17:195-201.
32. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006;12:4794-803.
33. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13.
34. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-11.
35. + T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
36. + regulatory T cell function. Science 2005;309:1380-4.
37. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006;177:6584-7.
38. Alsharifi M, Regner M, Blanden R, et al. Exhaustion of type I interferon response following an acute viral infection. J Immunol 2006;177:3235-41.
39. Bjorck P. Dendritic cells exposed to herpes simplex virus in vivo do not produce IFN-α after rechallenge with virus in vitro and exhibit decreased T cell alloreactivity. J Immunol 2004;172:5396-404.
40. Medvedev AE, Sabroe I, Hasday JD, Vogel SN. Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res 2006;12:133-50.
41. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992;52:3528-33.
42. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156:337-45.
43. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumor-directed treatment for melanoma. Br J Dermatol 2006;155:1287-92.